CD8A and hepatocellular carcinoma: found that HCC with high expression of PD-L1, VEGFR and infiltrating CD8+ T cell had better benefit from atezolizumab plus bevacizumab therapy than monotherapy (107), indicating that HCC patients with these features probably appropriate to combined immunotherapy.